4.5 Article

Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn

Journal

VACCINE
Volume 22, Issue 31-32, Pages 4385-4389

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2004.01.073

Keywords

transgenic plant; oral vaccine; E. coli

Funding

  1. NCRR NIH HHS [M01 RR165001] Funding Source: Medline
  2. NIAID NIH HHS [N01-AI-65299] Funding Source: Medline

Ask authors/readers for more resources

Previous clinical studies have demonstrated the feasibility of using edible transgenic plants to deliver protective antigens as new oral vaccines. Transgenic corn is particularly attractive for this purpose since the recombinant antigen is stable and homogeneous, and corn can be formulated in several edible forms without destroying the cloned antigen. Transgenic corn expressing 1 mg of LT-B of Escherichia coli without buffer was fed to adult volunteers in three doses, each consisting of 2.1 g of plant material. Seven (78%) of nine volunteers developed rises in both serum IgG anti-LT and numbers of specific antibody secreting cells after vaccination. Four (44%) of nine volunteers also developed stool IgA. Transgenic plants represent a new vector for oral vaccine antigens. (C) 2004 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available